title: Inhibitory action of methadone and its metabolites on erg-mediated K+ current in GH₃ pituitary tumor cells.
abstract: Methadone (Mtd) is a widely used opioid drug associated with the side effect of hyperprolactinemia. The mechanism of how Mtd induces prolactin secretion remains unclear. The effects of Mtd and its two main metabolites (EDDP: (±)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium percholarate and EMDP: 2-ethyl-5-methyl-3,3-dipnehyl-1-pyrroline) on ion currents were investigated in GH₃ pituitary tumor cells. Hyperpolarization-elicited K+ currents in GH₃ cells bathed in a high-K(+), Ca(2+)-free solution were studied to evaluate the effects of Mtd and other related compounds on the ether-à-go-go-related-gene (erg) K(+) current (I(K(erg))). Mtd suppressed the amplitude of I(K(erg)) in a concentration-dependent manner with an IC(50) value of 10.4 μM. With the aid of a minimal binding scheme, the inhibitory action of Mtd on I(K(erg)) was estimated with a dissociation constant of 8.2 μM. Mtd tended to increase the rate of I(K(erg)) deactivation in a voltage-dependent fashion. EDDP (10 μM) had no effect on I(K(erg)), while EMDP (10μM) slightly suppressed it. In GH₃ cells incubated with naloxone (30 μM), the Mtd-induced inhibition of I(K(erg)) remained unaltered. Under cell-attached voltage-clamp recordings, Mtd increased the frequency of spontaneous action currents with no change in current amplitude. Similarly, Mtd can suppress I(K(erg)) in differentiated NG108-15 cells; dynorphin A(1-13) did not reverse Mtd-induced inhibition of I(K(erg)). This study shows that Mtd has a depressant effect on I(K(erg)), and suggests its ability to affect membrane excitability and prolactin secretion. The cyclization of Mtd, in which EDDP and EMDP are formed, tends to be critical in removal of the Mtd binding to erg K+ channel.
authors.affiliation: College of Medical and Health Sciences, Fooyin University, Ta-Liao, Kaohsiung County, Taiwan.
authors.forename: Mei-Han
authors.initials: MH
authors.lastname: Huang
authors.forename: Ai-Yu
authors.initials: AY
authors.lastname: Shen
authors.forename: Trey-Shy
authors.initials: TS
authors.lastname: Wang
authors.forename: Hui-Ming
authors.initials: HM
authors.lastname: Wu
authors.forename: Ya-Fei
authors.initials: YF
authors.lastname: Kang
authors.forename: Chia-Tai
authors.initials: CT
authors.lastname: Chen
authors.forename: Tai-I
authors.initials: TI
authors.lastname: Hsu
authors.forename: Bing-Shuo
authors.initials: BS
authors.lastname: Chen
authors.forename: Sheng-Nan
authors.initials: SN
authors.lastname: Wu
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors*; D008691:Methadone / Q000378:metabolism / Q000633:toxicity*; D009270:Naloxone / Q000494:pharmacology; D009294:Narcotics / Q000633:toxicity*; D009474:Neurons / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology; D011388:Prolactin / Q000378:metabolism; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D018967:Risperidone / Q000494:pharmacology
chemical_list: C103254:2-ethyl-5-methyl-3,3-diphenylpyrroline; D051638:Ether-A-Go-Go Potassium Channels; D009294:Narcotics; D011759:Pyrrolidines; D009270:Naloxone; D011388:Prolactin; D018967:Risperidone; D008691:Methadone; C010724:2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine